TUESDAY, Feb. 14, 2023 (HealthDay News) -- The chronic obstructive pulmonary disease (COPD) Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) screening tool has low sensitivity and high specificity for identifying clinically significant COPD, according to a study published in the Feb. 14 issue of the Journal of the American Medical Association.

Fernando J. Martinez, M.D., from Weill Cornell Medicine/NY Presbyterian Hospital in New York City, and colleagues enrolled 4,325 primary care patients aged 45 to 80 years without a prior COPD diagnosis between Oct. 12, 2018, and April 1, 2022. The CAPTURE tool's sensitivity and specificity for identifying patients with undiagnosed, clinically significant COPD was assessed.

The researchers found that 53 of the 110 patients (2.5 percent) with undiagnosed, clinically significant COPD had a positive screening result, with sensitivity and specificity of 48.2 and 88.6 percent, respectively. For varying positive screening thresholds, the area under the receiver operating characteristic curve was 0.81.

"Further research is needed to optimize performance of the screening tool and to understand whether its use affects clinical outcomes," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including several that funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Source link